Thalidomide treatment of chronic erythema multiforme

Authors

  • Federico Pastore Dr. Enrique Tornú Hospital, César Milstein Institute, Autonomous City of Buenos Aires, Argentina

DOI:

https://doi.org/10.47196/da.v28i2.2358

Abstract

Erythema multiforme can evolve into a recurrent or persistent form. Valaciclovir is the first-line treatment in these cases. There is no consensus regarding the choice of a second line of treatment when this fails.

The efficacy of thalidomide for the treatment of chronic erythema multiforme (recurrent and persistent) was evaluated in adult patients who had had at least one treatment failure prior to the use of this drug.

After 6 months of treatment with thalidomide, 66% of patients were in complete remission, 14% had discontinued treatment, and 7% had experienced at least one flare.

The mean dose used was 50 mg/day.

Author Biography

Federico Pastore, Dr. Enrique Tornú Hospital, César Milstein Institute, Autonomous City of Buenos Aires, Argentina

Dermatologist and Legist, Dermatology Plant Physician, Dr. Enrique Tornú Hospital, Head of the Dermatology Service, César Milstein Institute, Autonomous City of Buenos Aires

References

I. Roux C, Sbidian E, Bouaziz JD, Kottler D, et ál. Evaluation of Thalidomide Treatment of Patients With Chronic Erythema Multiforme: A Multicenter Retrospective Cohort Study. JAMA Dermatology. 2021;157:1472-1476.

Revista de la Sociedad Argentina de Dermatología N° 2 de 2022

Downloads

Published

2022-06-01

Issue

Vol. 28 No. 2 (2022): April-June 2022

Section

Dermatological Pearls

License

Copyright (c) 2022 Argentine Society of Dermatology

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

El/los autor/es tranfieren todos los derechos de autor del manuscrito arriba mencionado a Dermatología Argentina en el caso de que el trabajo sea publicado. El/los autor/es declaran que el artículo es original, que no infringe ningún derecho de propiedad intelectual u otros derechos de terceros, que no se encuentra bajo consideración de otra revista y que no ha sido previamente publicado.

 

Le solicitamos haga click aquí para imprimir, firmar y enviar por correo postal la transferencia de los derechos de autor